Kanwar Nasir M. Khan, DVM, PhD
Presented June 7, 2008
Oath and Hooding Ceremony
Mershon Auditorium
Kanwar Nasir M. Khan, DVM, PhD
Dr. Kanwar Nasir M. Khan received his Doctor of Veterinary Medicine degree in 1982 from the University of Agriculture in Faisalabad, Pakistan. He continued his studies there and completed a Master of Science degree in Veterinary Pathology in 1985. After practicing veterinary medicine for three and a half years, he came to The Ohio State University as a graduate student the College of Veterinary Medicine. During his four years of doctoral studies he made important original contributions to the research field of virus mediated suppression of hematopoiesis. He went on to receive his Doctor of Philosophy (Hematology) degree in 1992. He is a diplomate of both the American College of Veterinary Pathologists and the American Board of Toxicology.
Since graduating from Ohio State, Dr. Khan has distinguished himself as a biological science expert in the pharmaceutical industry with such companies as G.D. Searle, Monsanto, Pharmacia, and Zoetis (formally Pfizer). Dr. Khan's areas of expertise include hematopoiesis, renal pathology, regulatory drug development, and management of projects. He has been the lead toxicologist and pathologist for a number of compounds in inflammation, pain, cardiovascular, CNS, anti-infective, respiratory/allergy, and oncology therapeutic areas. Dr. Khan is also recognized world-wide as an expert in the non-clinical development of anti-inflammatory products. He was pivotal in the development timeline for Celebrex, which registered in less than four years after filing of the initial new drug application.
Dr. Khan is currently Vice President, Drug Safety R&D, for Zoetis (formally Pfizer) Global Research & Development in Groton, Connecticut. His work involves the determination of regulatory strategy and for review and decisions on the portfolio of drugs in development, as well as molecules considered as candidates for development. During his career he has authored over 120 manuscripts and several book chapters.
Dr. Khan's work represents the highest ideals in a biological science expert. He strives to discover the truth about pharmaceutical drug risks, then works skillfully and diligently to make the truth emerge as the preeminent factor in decision making.
